Novotech Secures New Investment from GIC, Temasek, and TPG to Boost Global Growth Novotech, a leading full-service biotech clinical research organization (CRO), announced today that affiliates of GIC and Temasek have entered into binding agreements to acquire a significant stake…
ACC 2025: Sensydia CPS™ Accurately Assesses Mean Pulmonary Artery Pressure Non-Invasively Sensydia, a clinical-stage company focused on non-invasive cardiac assessments, recently showcased promising clinical findings from a study on its AI-powered Cardiac Performance System (CPS™) at the American College of…
Colorectal Cancer Screening and Diagnostics Market Report Summary Market Overview The “Colorectal Cancer Screening and Diagnostics Market” report provides an in-depth analysis of the colorectal cancer screening and diagnostic testing industry. This comprehensive study includes a market snapshot, company profiles…
Altasciences Wins 2025 CDMO Leadership Award for Small Molecule Dosage Forms Altasciences, a recognized leader in contract development and manufacturing (CDMO) services, has been honored with the 2025 CDMO Leadership Award in the Small Molecule Dosage Form–North America category. This…
CRISPR Cas9 Market Set for Exponential Growth with Gene Therapy Advancements The latest “CRISPR Cas9 Market” report has been added to ResearchAndMarkets.com’s offerings, highlighting the transformative potential of CRISPR/Cas9 technology in medicine and biotechnology. This breakthrough gene-editing tool is set…
Global Cancer Antibody Drug Conjugates Market Poised for $40 Billion Growth by 2030 The global market for cancer antibody-drug conjugates (ADCs) is experiencing rapid growth, with projections indicating an increase of $40 billion between 2023 and 2030. According to the…
Bristol Myers Squibb’s Opdivo-Based Perioperative Regimen Receives Positive CHMP Opinion for Resectable NSCLC Bristol Myers Squibb (NYSE: BMY) has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive…
Health Canada Approves 4Moving Biotech’s Phase 2a Trial for Knee Osteoarthritis 4Moving Biotech (4MB), a pioneering biotechnology company and a spin-off of 4P-Pharma, has received authorization from Health Canada to initiate its Phase 2a INFLAM MOTION clinical trial. This study…
Curatis Achieves 30% Sales Growth & Expands C-PTBE-01 Patient Reach Curatis Holding AG (SIX:CURN, ‘Curatis’) has reported strong business performance in 2024, achieving business revenues of CHF 6.9 million, with Curatis AG contributing to these figures for only eight months.…
Celltrion’s Remdantry™ Set for Canada Launch on April 1, 2025 Celltrion, Inc., a global biopharmaceutical leader, has announced that its biosimilar Remdantry™ will be available in Canada starting April 1, 2025. Previously marketed under the name Inflectra®, Remdantry™ represents the…